Research programme: gene therapy - MeiraGTx

Drug Profile

Research programme: gene therapy - MeiraGTx

Alternative Names: A-003 - MeiraGTx; A-005; A-006 - MeiraGTx; A-007 - MeiraGTx; AAV2/8-hRKp.RPGR

Latest Information Update: 01 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MeiraGTx
  • Class Gene therapies
  • Mechanism of Action Gene transference; Platelet-derived growth factor beta receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis; Colour vision defects; Dry age-related macular degeneration; Wet age-related macular degeneration

Most Recent Events

  • 01 Sep 2016 Preclinical trials in Amyotrophic lateral sclerosis in USA (Parenteral) before September 2016
  • 01 Sep 2016 Preclinical trials in Colour vision defects in USA (Intraocular) before September 2016
  • 01 Sep 2016 Preclinical trials in Dry age-related macular degeneration in USA (Parenteral) before September 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top